Seagen Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SEAGEN
SEAGEN has one approved drug.
There are seven US patents protecting SEAGEN drugs.
There are one hundred and sixty-five patent family members on SEAGEN drugs in forty-four countries and nineteen supplementary protection certificates in seventeen countries.
Summary for Seagen
| International Patents: | 165 |
| US Patents: | 7 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Seagen
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-001 | Apr 17, 2020 | RX | Yes | No | 11,666,572 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-001 | Apr 17, 2020 | RX | Yes | No | 9,457,093 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | 12,048,698 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Seagen | TUKYSA | tucatinib | TABLET;ORAL | 213411-002 | Apr 17, 2020 | RX | Yes | Yes | 11,504,370 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Seagen Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Canada | 2632194 | ⤷ Start Trial |
| Japan | 7328151 | ⤷ Start Trial |
| Australia | 2010202330 | ⤷ Start Trial |
| South Korea | 20080070064 | ⤷ Start Trial |
| Cyprus | 1112754 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Seagen Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1971601 | 301113 | Netherlands | ⤷ Start Trial | PRODUCT NAME: TUCATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT OF SOLVAAT; REGISTRATION NO/DATE: 67798 20200507 |
| 1971601 | LUC00217 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: TUCATINIB EVENTUELLEMENT SOUS FORME D'UN SEL OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/20/1526 20210212 |
| 1971601 | 770 | Finland | ⤷ Start Trial | |
| 1971601 | 21C1031 | France | ⤷ Start Trial | PRODUCT NAME: TUCATINIB, OPTIONNELLEMENT SOUS LA FORME D'UN SEL OU D'UN SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/20/1526 20210212 |
| 1971601 | C202130042 | Spain | ⤷ Start Trial | PRODUCT NAME: TUCATINIB, OPCIONALMENTE EN FORMA DE UNA SAL O SOLVATO ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/20/1526; DATE OF AUTHORISATION: 20210211; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1526; DATE OF FIRST AUTHORISATION IN EEA: 20210211 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
